TACE Drug Protocol

DRUG3 trials

Sponsors

Sun Yat-sen University

Conditions

HepatoCellular CarcinomaHepatocellular Carcinoma

Phase 2

HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B

CompletedNCT03048123

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2015-10-01End: 2017-01-24Updated: 2017-02-09

Phase 3

HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.

CompletedNCT02973685

Sun Yat-sen UniversityHepatoCellular Carcinoma

Start: 2016-10-01End: 2020-11-28Updated: 2023-06-12

Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria

WithdrawnNCT03791918

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2019-01-01End: 2022-01-01Updated: 2019-05-02

Related Papers

Supplementary Figure S1 from HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study

2026-02-17

Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.

Journal of Clinical Oncology2025-05-281 citations

Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib plus transarterial chemoembolization in advanced hepatocellular carcinoma: An update on SHATA-001 study.

Journal of Clinical Oncology2025-05-28

A Contrast‐Enhanced Ultrasound Cine‐Based Deep Learning Model for Predicting the Response of Advanced Hepatocellular Carcinoma to Hepatic Arterial Infusion Chemotherapy Combined With Systemic Therapies

Cancer Science2025-04-29

Sorafenib plus hepatic arterial infusion of oxaliplatin and fluorouracil vs sorafenib plus transarterial chemoembolization for advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase III trial (SHATA-001).

Journal of Clinical Oncology2024-06-011 citations